

# COVID-19-like symptoms and their relation to the SARS-CoV-2 epidemic in children and adults of an Italian birth cohort

## Sintomi tipici di COVID-19 nei bambini e negli adulti della coorte di nascita italiana NINFEA e loro relazione con l'epidemia di SARS-CoV-2

Maja Popovic,<sup>1</sup> Chiara Moccia,<sup>1</sup> Elena Isaevska,<sup>1</sup> Giovenale Moirano,<sup>1</sup> Costanza Pizzi,<sup>1</sup> Daniela Zugna,<sup>1</sup> Franca Rusconi,<sup>2</sup> Franco Merletti,<sup>1</sup> Milena Maule,<sup>1</sup> Lorenzo Richiardi<sup>1</sup>

<sup>1</sup> Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and Reference Centre for Epidemiology and Cancer Prevention in Piedmont (CPO Piemonte), Turin (Italy)

<sup>2</sup> Unit of Epidemiology, Meyer Children's University Hospital, Florence (Italy)

**Corresponding author:** Maja Popovic; maja.popovic@unito.it

### WHAT IS ALREADY KNOWN

- A number of cases positive for SARS-CoV-2 escape surveillance systems, especially in the first epidemic waves and/or when the number of cases becomes too large to allow complete diagnostic coverage.
- Some web-based surveys have been launched to explore the population prevalence of COVID-19-like symptoms, but these surveys, generally based on volunteers, have no information on the response proportion and are prone to selection bias when aiming to estimate the population prevalence.

### WHAT THIS STUDY ADDS

- In the 6-8 weeks since the first known autochthonous Italian COVID-19 case, more than a half of the interviewed families had at least one family member with at least one COVID-19-like symptom.
- There is a strong correlation between the prevalence of muscle pain, fatigue, low-grade fever, and breathing difficulties in adults and the population cumulative number of SARS-CoV-2 cases.
- There is a clear pattern of familiar symptom aggregation among adults with at least one family member diagnosed with COVID-19, while in children exposure to COVID-19 within the family is associated with a strongly increased prevalence of low-grade fever and anosmia/dysgeusia, but with no other symptoms

**RESULTS:** information was collected on 3,184 households, 6,133 adults, and 5,751 children. In the period March-April 2020, 55.4% of the NINFEA families had at least one member with at least one COVID-19-like symptom. There was a strong geographical correlation between the population cumulative incidence of COVID-19 and the prevalence of muscle pain, fatigue, low-grade fever, and breathing difficulties in adults (Spearman's rho  $\geq 0.70$ ). Having at least one family member with a COVID-19 diagnosis, compared with none tested for SARS-CoV-2, was associated with an increased prevalence ratio (PR) of almost all COVID-19-like symptoms in adults, and only of low-grade fever (37-37.5°C; PR 4.54; 95%CI 2.20-9.40) and anosmia/dysgeusia in children. Among adults with COVID-19 diagnosis, fatigue, muscle pain, and fever had a sensitivity  $\geq 70\%$ . In individuals tested for SARS-CoV-2, with a 16.6% prevalence of COVID-19, breathing difficulties and nausea/vomiting had the highest PPVs, with point estimates close to 60%, and with NPVs close to 90%.

**CONCLUSIONS:** the geographical prevalence of COVID-19-like symptoms in adults may inform on local disease clusters, while certain symptoms in family members of confirmed COVID-19 cases could help identify the intra-familial spread of the virus and its further propagation in the community. Low-grade fever is frequent in children with at least one household member with COVID-19 and possibly indicates child infection.

**Keywords:** COVID-19, SARS-CoV-2, symptoms, Italy, NINFEA cohort

### ABSTRACT

**OBJECTIVES:** to estimate the population prevalence of COVID-19-like symptoms in children and adults during the first SARS-CoV-2 epidemic wave hitting Italy in the spring 2020; to assess their geographical correlation with the cumulative number of COVID-19 cases by province; to analyse their clustering within families; to estimate their sensitivity, positive predictive value (PPV) and negative predictive value (NPV) for COVID-19 diagnosis in individuals tested for SARS-CoV-2.

**DESIGN:** cross-sectional study nested within a birth cohort.

**SETTING AND PARTICIPANTS:** mothers participating in an Italian birth cohort (NINFEA) were invited to complete an online questionnaire on COVID-19-like symptoms in their household.

**MAIN OUTCOME MEASURES:** population prevalence of COVID-19-like symptoms in children and adults, geographical correlation of COVID-19-like symptoms with the cumulative number of COVID-19 cases by province, clustering of COVID-19-like symptoms within families, and sensitivity, PPV and NPV of COVID-19-like symptoms for COVID-19 diagnosis in individuals tested for SARS-CoV-2.

### RIASSUNTO

**OBIETTIVI:** indagare la prevalenza dei sintomi tipici del COVID-19 nella popolazione pediatrica e adulta durante la prima ondata epidemica di SARS-CoV-2 che ha colpito l'Italia nella primavera 2020; valutare la loro correlazione geografica con il numero cumulativo di casi di COVID-19 per provincia; analizzare il *clustering* dei sintomi all'interno delle famiglie; stimare la loro sensibilità, il valore predittivo positivo (PPV) e il valore predittivo negativo (NPV) per la diagnosi di COVID-19 tra gli individui testati per SARS-CoV-2.

**DISEGNO:** studio trasversale annidato all'interno di una coorte di nascita.

**SETTING E PARTECIPANTI:** nell'aprile 2020, le madri partecipanti alla coorte NINFEA sono state invitate a completare un questionario anonimo online sui sintomi tipici del COVID-19 nei membri della propria famiglia.

**PRINCIPALI MISURE DI OUTCOME:** la prevalenza dei sintomi tipici del COVID-19 nella popolazione pediatrica e adulta, la

loro correlazione geografica con il numero cumulativo di casi di COVID-19 per provincia, la sensibilità, il PPV e il NPV per la diagnosi di COVID-19 tra gli individui testati per SARS-CoV-2.

**RISULTATI:** lo studio ha coinvolto 6.133 adulti e 5.751 bambini, per un totale di 3.184 famiglie. Nel periodo marzo-aprile 2020, il 55,4% delle famiglie NINFEA aveva almeno un membro con almeno un sintomo tipico del COVID-19. È emersa una forte correlazione geografica tra l'incidenza cumulativa di COVID-19 nella popolazione e la prevalenza di dolori muscolari, stanchezza, febbre bassa e difficoltà respiratorie negli adulti (rho di Spearman  $\geq 0,70$ ). Avere almeno un membro della famiglia con diagnosi di COVID-19, rispetto all'assenza nel nucleo familiare di persone che hanno effettuato un test, è risultata associata negli adulti con un aumento del rapporto di prevalenza di quasi tutti i sintomi tipici del COVID-19, mentre nei bambini solo con febbre bassa (37-37.5 °C; rapporto di pre-

valenza 4,54; IC95% 2,20-9,40) e anosmia/disgeusia. Tra gli adulti con COVID-19, stanchezza, dolore muscolare e febbre avevano una sensibilità  $\geq 70\%$ . Negli individui testati per SARS-CoV-2, con una prevalenza di COVID-19 del 16,6%, difficoltà respiratorie e nausea/vomito hanno avuto i PPV più alti, con stime puntuali vicine al 60% e con NPV vicini al 90%.

**CONCLUSIONI:** la prevalenza geografica dei sintomi tipici del COVID-19 nella popolazione adulta potrebbe essere rilevante per l'identificazione di focolai epidemici futuri. I sintomi nei familiari di casi confermati di COVID-19 potrebbero aiutare a identificare la diffusione intrafamiliare del virus e la sua ulteriore propagazione nella comunità. In particolare, la febbre bassa è frequente nei bambini con almeno un membro della famiglia con COVID-19 e probabilmente indica un'infezione infantile.

**Parole chiave:** COVID-19, SARS-CoV-2, sintomi, Italia, coorte NINFEA

## INTRODUCTION

It is recognized that a substantial number of cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) remain undiagnosed, escaping surveillance systems. These mainly include asymptomatic individuals and patients with mild or subclinical presentations that likely represent the majority of patients, especially among children.<sup>1,2</sup> Reported symptoms of Coronavirus disease 2019 (COVID-19) include fever, cough, sore throat, shortness of breath, myalgia, fatigue, diarrhoea, nausea or vomiting, and headache.<sup>3,4</sup> In particular, loss of smell (anosmia) and taste (dysgeusia) have been reported to be highly suggestive of SARS-CoV-2 infection.<sup>5,6</sup>

Even if symptoms of COVID-19 play an important role in seeking healthcare assistance or self-isolation and informing the testing and diagnostic workflow,<sup>7</sup> their population-based prevalence has been less investigated. Likewise, it is unclear whether this prevalence may inform on the spread of the disease beyond surveillance systems. This is particularly true in children, who rarely have a severe form of the disease and, thus, are seldom tested for SARS-CoV-2 outside the investigation of clusters, for example at schools. As a consequence, children represent a rather small proportion of all reported diagnosed COVID-19 cases (e.g., children 0-9 years: 3.2% in Italy as of 27.10.2020);<sup>8</sup> but may play an important role in the spread of the disease and contribute to herd immunity. Based on the preliminary results of an Italian national seroprevalence study conducted in May-June 2020,<sup>9</sup> it can be estimated that, in the age group 0-19 years, out of 100 cases only 2.5 were actually diagnosed, while the same estimate in adults ( $\geq 20$  years) was 18.9%.

Some web-based surveys have been launched to explore the population prevalence of COVID-19-like symptoms. Many of these surveys, however, recruit volunteers online with no information on the response proportion. Thus, they are prone to selection bias when aiming to estimate the population prevalence, as individuals with specific symp-

toms or who experienced those symptoms in the recent past may be more or less likely to volunteer than asymptomatic individuals. Additionally, some ad-hoc web-based cohorts have been established; in these cohorts, volunteer participants report their symptoms on a regular basis.<sup>10</sup> This design is less affected by selection bias as participants may be enrolled before the onset of the symptoms.

The first confirmed autochthonous COVID-19 case in Italy was identified on 21.02.2020. To explore the relationship between reported COVID-19-like symptoms and the registered COVID-19 diagnoses in children and adults during the first epidemic wave in Italy, on 07.04.2020, we invited the participants of an Italian NINFEA (*Nascita e Infanzia: gli Effetti dell'Ambiente*; Birth and Childhood: Effects of the Environment) birth cohort involving women recruited during pregnancy between 2005 and 2016 and their families to complete a short online questionnaire on COVID-19, with a particular focus on symptoms. The questionnaire closed on 20.04.2020, after 13 days. In this paper, the aims are:

1. to explore the geographical correlation between the population prevalence of COVID-19-like symptoms in the adults and children of the cohort during the initial phases of the epidemic and the cumulative number of new SARS-CoV-2 positive cases reported by the surveillance system;
2. to analyse the clustering of symptoms within families, with or without a member who tested negative for SARS-CoV-2 or was diagnosed with COVID-19;
3. to estimate the sensitivity, positive and negative predictive values for COVID-19-like symptoms in the tested individuals of the NINFEA population.

## METHODS

### STUDY DESIGN AND POPULATION

The NINFEA study is an Italian internet-based mother-child cohort ([www.progettoninfea.it](http://www.progettoninfea.it)) set up to investigate the influence of early-life exposures on later childhood and adulthood health. Between 2005 and 2016, approximately

7,500 pregnant women were recruited by completing the baseline questionnaire, and the children are currently followed-up with questionnaires completed by mothers at 6 and 18 months after delivery and when the children turn 4, 7, 10, and 13 years. Details on the cohort have been published before.<sup>11-14</sup>

The NINFEA study was approved by the Ethical Committee of the San Giovanni Battista Hospital and CTO/CRF/Maria Adelaide Hospital of Turin (project number 45). Parental written, web-based consent was obtained at enrolment, after completing each study follow-up questionnaire, and additional parental written consent was obtained at the moment of biological samples collection. A specific amendment to the Ethical Committee was submitted for the COVID-19 survey and, although survey was anonymous, an online informed consent was anyhow obtained by the participants who filled in the questionnaire.

### COVID-19 SURVEY

Women who completed at least the first NINFEA follow-up questionnaire (when their children were 6 months old; No. 5,879) were invited to complete an anonymous online questionnaire to assess the prevalence of COVID-19-like symptoms in their households. A first e-mail was sent out on 07.04.2020, approximately 5 weeks after the Italian government imposed the national lockdown. The questionnaire remained open for 13 days (until 20.04.2020) and, during this period, two reminder e-mails were sent. The questionnaire consisted of background information on respondents' age, gender, year of recruitment into the NINFEA cohort, education level, province, region and area of residence, and the source from which information on COVID-19 was sought. The second part of the questionnaire asked about family composition and gender and age of family members; and included a checklist of COVID-19-like symptoms since the day of the first reported case in Italy (21.02.2020) and, in the last week, for each close family member (mother, partner, and each child <18 years old). The symptoms included: nasal congestion, low-grade fever (37.0-37.5°C), fever (>37.5°C), cough, sore throat, nausea/vomiting, diarrhoea, muscle pain, and fatigue. Questions on breathing difficulties and loss of smell or taste (anosmia/dysgeusia) were introduced a few days after launching the questionnaire and are available for 64.2% of the respondents. Information on SARS-CoV-2 testing (using nasopharyngeal swabs and real-time reverse transcription polymerase chain reaction [RT-PCR]) and COVID-19 diagnosis for each of the close family members and other people living in the same household were also collected. An English version of the questionnaire is provided in Box S1 (see online supplementary materials).

### ADMINISTRATIVE DATA

The population cumulative incidence of new SARS-CoV-2 positive cases until 07.04.2020 by province was obtained

from the national surveillance system data available at the website of the Italian Ministry of Health/Civil Protection Department,<sup>15</sup> province population size (all residents as of 01.01.2020) was obtained from the Italian National Institute of Statistics.<sup>16</sup>

### STATISTICAL ANALYSES

To account for survey non-response, weights for each respondent were calculated using iterative proportional fitting,<sup>17</sup> allowing the distribution of the survey variables to closely resemble the known NINFEA population margins. The weights were calculated using the following maternal characteristics:

- age: <35 years, 35-40 years, 40-45 years, 45-50 years and ≥50 years;
- education level: low (primary school or less), medium (secondary school), high (university degree or higher);
- period of enrolment in the NINFEA study: 2005-2008, 2009-2012, 2013-2016.

Using the estimated weights, descriptive statistics were calculated for sociodemographic characteristics, cumulative symptoms, SARS-CoV-2 testing, and COVID-19 diagnosis separately for children aged <6 years, children aged 6-11 years, adolescents (12-17 years), and adults.

To explore the geographical correlation between the prevalence of COVID-19-like symptoms and the population cumulative number of newly reported SARS-CoV-2 cases, firstly the predicted probability of each symptom given the province of residence was estimated using weighted logistic regression models and accounting for family clusters. These analyses were performed only in provinces with more than 50 study subjects (Piedmont: Alessandria, Asti, Cuneo, Torino; Lombardy: Milan; Tuscany: Arezzo, Lucca, Florence; Lazio: Rome). The predicted probabilities were correlated to the corresponding province cumulative incidences per 1,000 inhabitants (as of 07.04.2020) using Spearman's rank correlation coefficients. These analyses were performed separately in children and adolescents (<6 years, 6-11 years, and 12-17 years), in adults, and at the household-level.

To analyse the clustering of symptoms within families exposed to SARS-CoV-2, a three-level exposure variable was defined as:

1. no family/household member tested for SARS-CoV-2;
2. at least one tested member but none with COVID-19;
3. at least one member being diagnosed with COVID-19.

This exposure was analysed in association with the presence of each COVID-19-like symptom, separately in children (0-17 years) and in adults. The prevalence ratios, with corresponding 95% CIs, was estimated using weighted Poisson regression models with cluster-robust standard errors to account for the family structure. Models were adjusted for gender, age, maternal education level (low, medium, high), family size (2, 3, 4, and ≥5 members), area of residence (urban, suburban, and rural), region of residence (Piedmont, Tuscany, Lombardy, other regions of Northern Italy, Cen-

tral Italian regions, Southern Italian regions, and abroad), and maternal age (for analysis of children). Two sensitivity analyses were performed: excluding all reported COVID-19 cases in the analyses based on adults and considering only children older than 6 years of age in the analyses based on children. Further stratification by child age group was not possible due to small number of exposed cases.

For each symptom, sensitivity for COVID-19 was calculated among NINFEA adults and its positive (PPV) and negative (NPV) predictive values among NINFEA adults tested for SARS-CoV-2. As more than 60% of the NINFEA participants comes from Piedmont, one of the Italian regions most affected by COVID-19, the analyses were repeated restricted to Piedmont residents. For these, also the population PPV of each symptom was also estimated.

All analyses were conducted using Stata version 15.1 (College Station, Texas, USA).

## RESULTS

The descriptive characteristics of the study population are shown in Table 1. A total of 3,184 NINFEA participants responded to the COVID-19 survey, which corresponds to 54.2% of the invited population. Their characteristics, including age, region of residence, and year of enrolment in the NINFEA cohort, were similar to those of the NINFEA cohort at baseline. Information was collected on 3,184 households, 6,133 adults, and 5,751 children.

Table 2 reports the weighted prevalence of COVID-19-like symptoms during the study period, separately for children aged <6 years, children aged 6-11 years, adolescents (12-17 years), adults, and at the household level. More than half of the families (55.4%) had at least one member with at least one COVID-19-like symptom. The most prevalent symptoms in adults were: fatigue (16.5%), sore throat (14.5%), cough (13.8%), nasal congestion (13.2%), and muscle pain (11.4%). Among children, the most common symptoms were nasal congestion, cough, and fever >37.5°C, and, in adolescents, additionally sore throat and fatigue. There was no evidence of an association between time to response and the prevalence of symptoms in adults or children (all *p*-values >0.05).

A total of 169 (2.6%) adults and 14 (0.2%) children were tested for SARS-CoV-2 using nasopharyngeal swabs. Twenty-eight adults (16.6%) tested positive and 2 additional subjects reported COVID-19 diagnosis without RT-PCR COVID-19 test. No information was available on diagnostic criteria for these two subjects. Thus, a total of 30 NINFEA adults (0.5%), 20 females and 10 males, were diagnosed with COVID-19. Among children, only one 5-year-old child, with both parents positive, tested positive for COVID-19.

## GEOGRAPHICAL CORRELATION BETWEEN POPULATION COVID-19 INCIDENCE AND PREVALENCE OF COVID-19-LIKE SYMPTOMS, TESTING FOR SARS-COV-2 AND COVID-19 DIAGNOSIS IN THE NINFEA POPULATION

A strong geographical correlation was observed between the population cumulative incidence of SARS-CoV-2 cases as of 07.04.2020 and the prevalence of COVID-19 diagnosis among NINFEA participants (Spearman's rho 0.80, based only on 4 provinces), and a low correlation with SARS-CoV-2 testing prevalence (Table 3 and Figure S1).

There was a high correlation between the population SARS-CoV-2 cumulative incidence and the prevalence of muscle pain, fatigue, low-grade fever, and breathing difficulties in the NINFEA adult population, especially in men (all Spearman's rho  $\geq 0.70$ ) (see Table 3, Figures S2, and Table S1 for analyses stratified by gender). There was no clear evidence of correlation in children, apart from muscle pain across all age groups and fatigue in older children and adolescents (Table 3). Adolescent low-grade fever was also correlated with the population SARS-CoV-2 cumulative incidence.

## CLUSTERING OF COVID-19-LIKE SYMPTOMS WITHIN FAMILIES THAT TESTED NEGATIVE FOR SARS-COV-2 AND FAMILIES DIAGNOSED WITH COVID-19

An adjusted prevalence ratio of low-grade fever of 4.54 (95% CI: 2.20; 9.40) was found for children having at least one family member with a COVID-19 diagnosis, compared with children with no family members tested for SARS-CoV-2. There was also a high prevalence ratio of anosmia/dysgeusia (24.5; 95%CI 3.47-172.9) based only on 2 exposed cases. Similar findings were observed when the population was restricted only to children older than 6 years of age (Table S2). There was no clear evidence of association with other symptoms (Table 4), including muscle pain and fatigue, the only symptoms in children showing a high ecological (province-level) correlation with the population SARS-CoV-2 cumulative incidence. However, muscle pain and fatigue in children were strongly associated with muscle pain and fatigue in their parents (data not shown), suggesting that these may just be proxies of the same symptoms in parents.

Increased prevalence ratios were found for almost all COVID-19-like symptoms when comparing adults with at least one family member with a COVID-19 diagnosis with those whose household members were not tested for SARS-CoV-2 (Table 4). Particularly high prevalence ratios were found for breathing difficulties (14.4; 95%CI 7.98-26.0), anosmia/dysgeusia (13.64; 95%CI 7.34-25.4), and fever >37.5°C (8.68; 95%CI 6.10-12.3). Most of these associations remained after the exclusion of all reported COVID-19 cases to assess whether the observed prevalence ratios were due to the positive COVID-19 family member(s) (Table 4, last row).

CHARACTERISTICS		N. <sup>a</sup>	WEIGHTED PREVALENCE (95%CI) / WEIGHTED MEAN (SD) <sup>b</sup>	
<b>TOTAL NUMBER OF FAMILIES</b>		3,184	–	
<b>TOTAL NUMBER PARENTS</b>		6,133	–	
<b>TOTAL NUMBER OF CHILDREN (&lt;18 YEARS)</b>		5,751	–	
<b>GENDER (PARENTS)</b>	Female	3,178	51.9	(51.6-52.2)
	Male	2,955	48.1	(47.8-48.4)
<b>SINGLE PARENT</b>	Yes	235	7.6	(6.7-8.6)
	No	2,949	92.4	(91.4-93.3)
<b>GENDER (CHILDREN)</b>	Female	2,788	48.9	(47.6-50.2)
	Male	2,917	51.1	(49.8-52.4)
<b>MATERNAL AGE</b>	Total	3,169	41.9	(5.0)
	<35 years	201	7.4	(6.5-8.5)
	35-40 years	746	24.1	(22.6-25.6)
	40-45 years	1,160	36.8	(35.1-38.5)
	45-50 years	839	25.5	(24.1-27.1)
	≥50 years	223	6.2	(5.4-7.0)
<b>PATERNAL AGE</b>	Total	2,931	44.6	(6.1)
	<35 years	106	4.0	(3.3-4.8)
	35-40 years	440	15.5	(14.2-16.9)
	40-45 years	911	31.3	(29.6-33.0)
	45-50 years	894	30.4	(28.7-32.1)
	≥50 years	580	18.9	(17.5-20.3)
<b>CHILD AGE</b>	Total	5,735	7.7	(3.7)
	<6 years	1,671	29.0	(27.7-30.3)
	6-11 years	3,096	54.7	(53.4-55.9)
	12-17 years	968	16.3	(15.3-17.4)
<b>MATERNAL EDUCATION LEVEL<sup>c</sup></b>	Low	94	4.8	(4.0-5.9)
	Medium	948	33.3	(31.7-35.1)
	High	2128	61.9	(60.1-63.6)
<b>FAMILY SIZE</b>	2 members	118	3.8	(3.2-4.5)
	3 members	875	27.0	(25.5-28.6)
	4 members	1,629	51.5	(49.4-52.9)
	≥ 5 members	562	18.1	(16.8-19.5)
<b>NUMBER OF CHILDREN &lt;18 YEARS IN THE HOUSEHOLD</b>	1 child	1,032	32.0	(30.4-33.7)
	2 children	1,808	56.8	(55.1-58.6)
	3 children	289	9.4	(8.4-10.5)
	4 children	55	1.8	(1.4-2.3)
<b>RESIDENTIAL AREA</b>	Urban	995	30.3	(28.7-31.9)
	Suburban	1,501	47.8	(46.0-49.5)
	Rural	687	21.9	(20.5-23.4)
<b>REGION OF RESIDENCE</b>	Piedmont	2,055	64.0	(62.3-65.7)
	Tuscany	640	20.6	(19.2-22.0)
	Lombardy	141	4.43	(3.8-5.2)
	Other regions of Northern Italy	160	5.2	(4.4-6.0)
	Central Italian regions	85	2.6	(2.1-3.3)
	Southern Italian regions	77	2.5	(2.0-3.1)
	Abroad	26	0.8	(0.5-1.1)

CI: confidence interval / intervallo di confidenza; SD: standard deviation / deviazione standard

<sup>a</sup>Total numbers may vary due to missing data. / I totali possono variare a causa di dati mancanti.

<sup>b</sup>Weighted for maternal age, education level, and year of the NINFEA cohort enrolment. / Pesato per l'età materna, il livello di istruzione e l'anno di reclutamento.

<sup>c</sup>Low: primary school or less; medium: secondary school; high: university degree or higher / Basso: scuola primaria o inferiore; medio: scuola secondaria; alto: laurea o superiore

**Table 1.** Descriptive statistics of the population under study.

**Tabella 1.** Statistiche descrittive della popolazione in studio.

SYMPTOMS / COVID-19 TEST AND DIAGNOSIS	CHILDREN <6 YEARS N. 1,671		CHILDREN 6-11 YEARS N. 3,096		ADOLESCENTS 12-17 YEARS N. 968		ADULTS N. 6,133		AT LEAST ONE FAMILY MEMBER N. 3,184	
	N.	WEIGHTED PREVALENCE (95%CI)	N.	WEIGHTED PREVALENCE (95%CI)	N.	WEIGHTED PREVALENCE (95%CI)	N.	WEIGHTED PREVALENCE (95%CI)	N.	WEIGHTED PREVALENCE (95%CI)
NASAL CONGESTION	252	14.9 (13.1-17.0)	305	9.7 (8.6-10.9)	67	6.7 (5.2-8.6)	809	13.2 (12.2-14.2)	831	26.0 (24.4-27.5)
FEVER 37.0-37.5°C	80	4.7 (3.7-6.0)	103	3.3 (2.7-4.1)	44	4.3 (3.1-5.9)	397	6.6 (5.9-7.3)	450	14.2 (13.0-15.5)
FEVER >37.5°C	189	11.1 (9.6-12.9)	242	7.7 (6.7-8.8)	57	5.9 (4.4-7.9)	349	5.7 (5.1-6.4)	561	17.6 (16.3-19.0)
SORE THROAT	94	5.7 (4.5-7.0)	202	6.5 (5.5-7.5)	76	7.8 (6.1-9.8)	892	14.5 (13.5-15.6)	836	26.2 (24.6-27.7)
COUGH	242	14.4 (12.6-16.5)	271	8.8 (7.8-10.0)	80	8.2 (6.5-10.3)	843	13.8 (12.8-15.8)	889	27.9 (26.4-30.0)
MUSCLE PAIN	32	1.9 (1.3-2.7)	107	3.5 (2.8-4.3)	43	4.5 (3.2-6.2)	700	11.4 (10.5-12.4)	597	18.8 (17.4-20.2)
FATIGUE	71	4.1 (3.2-5.3)	161	5.1 (4.3-6.1)	69	7.0 (5.4-8.9)	1,020	16.5 (15.4-17.6)	818	25.5 (24.0-27.1)
NAUSEA/VOMITING	45	2.5 (1.9-3.4)	107	3.4 (2.7-4.1)	24	2.4 (1.6-3.6)	178	2.9 (2.5-3.4)	278	8.7 (7.8-9.7)
DIARRHOEA	88	5.1 (4.0-6.3)	151	4.8 (4.0-5.6)	51	4.8 (3.6-6.4)	419	6.8 (6.1-7.6)	473	14.8 (13.6-16.1)
ANOSMIA/DYSGEUSIA <sup>a</sup>	3	0.3 (0.1-0.8)	4	0.2 (0.1-0.6)	5	0.8 (0.2-2.5)	95	2.4 (1.9-3.0)	86	4.1 (3.3-5.1)
BREATHING DIFFICULTIES <sup>a</sup>	9	0.8 (0.4-1.5)	11	0.6 (0.3-1.0)	7	1.3 (0.6-2.8)	101	2.6 (2.1-3.2)	104	5.2 (4.3-6.3)
AT LEAST ONE SYMPTOM <sup>b</sup>	491	28.9 (26.5-31.5)	743	23.7 (22.1-25.4)	230	23.1 (20.3-26.2)	2,275	37.0 (35.5-38.5)	1773	55.4 (53.7-57.2)
SARS-COV-2 TEST <sup>c</sup>	2	0.1 (0.0-0.4)	9	0.3 (0.2-0.5)	3	0.3 (0.1-1.0)	169	2.6 (2.2-3.1)	164	4.9 (4.2-5.7)
COVID-19 DIAGNOSIS	1	0.1 (0.0-0.4)	0	–	0	–	30	0.5 (0.3-0.7)	27	0.8 (0.6-1.2)

CI: confidence interval / intervallo di confidenza

<sup>a</sup> Based on 1,128 children aged <6 years, 1,955 children aged 6-11 years, 576 adolescents aged 12-17 years, 3,938 adults, and 2,044 families. / Basato su 1.128 bambini di età <6 anni, 1.955 bambini di 6-11 anni, 576 adolescenti di 12-17 anni, 3.938 adulti e 2.044 famiglie.  
<sup>b</sup> Excluding anosmia/dysgeusia and breathing difficulties. / Escludendo anosmia/dysgeusia e difficoltà respiratorie. <sup>c</sup> Nasopharyngeal swabs for SARS-CoV-2 testing. / Tampone rinofaringeo per test di SARS-CoV-2.

**Table 2.** COVID-19-like symptoms in the 6 weeks after 21.02.2020 in the NINFEA population.  
**Tabella 2.** Sintomi tipici del COVID-19 nella popolazione NINFEA nelle 6 settimane dopo il 21.02.2020.

SYMPTOMS / SARS-COV-2 TESTING AND COVID-19 DIAGNOSIS	CHILDREN <6 YEARS		CHILDREN 6-11 YEARS		ADOLESCENTS 12-17 YEARS		ADULTS		AT LEAST ONE FAMILY MEMBER	
	SPEARMAN'S RHO	P-VALUE	SPEARMAN'S RHO	P-VALUE	SPEARMAN'S RHO	P-VALUE	SPEARMAN'S RHO	P-VALUE	SPEARMAN'S RHO	P-VALUE
NASAL CONGESTION	-0.05	0.91	-0.08	0.83	-0.11	0.82	0.30	0.43	0.10	0.80
FEVER 37.0-37.5°C	-0.33	0.42	-0.08	0.83	<b>0.77</b>	0.07	<b>0.74</b>	0.04	0.22	0.58
FEVER >37.5°C	0.02	0.97	0.15	0.70	0.03	0.96	0.37	0.33	0.13	0.73
SORE THROAT	0.14	0.74	0.25	0.52	0.69	0.06	0.47	0.21	0.65	0.06
COUGH	-0.66	0.05	0.07	0.86	0.17	0.69	0.25	0.52	-0.02	0.97
MUSCLE PAIN	<b>0.71</b>	0.07	<b>0.74</b>	0.04	<b>0.80</b>	0.20	<b>0.88</b>	0.002	<b>0.97</b>	0.00
FATIGUE	0.39	0.38	<b>0.78</b>	0.01	<b>0.90</b>	0.04	<b>0.73</b>	0.02	0.65	0.06
NAUSEA/VOMITING	0.19	0.65	-0.10	0.82	0.30	0.62	0.12	0.77	0.38	0.31
DIARRHOEA	-0.09	0.82	0.25	0.52	<b>-0.80</b>	0.20	0.32	0.41	0.05	0.90
ANOSMIA/DYSGEUSIA	-0.50	0.67	–	–	–	–	0.52	0.18	0.52	0.18
BREATHING DIFFICULTIES	-0.50	0.67	-0.20	0.70	0.50	0.67	<b>0.76</b>	0.03	0.52	0.15
AT LEAST ONE SYMPTOM <sup>a</sup>	-0.47	0.21	0.50	0.17	-0.25	0.52	0.42	0.26	-0.30	0.43
SARS-COV-2 TEST <sup>b</sup>	–	–	-0.30	0.62	–	–	-0.33	0.42	0.15	0.70
COVID-19 DIAGNOSIS	–	–	–	–	–	–	<b>0.80</b>	0.20	<b>0.80</b>	0.20

In bold, correlation coefficients of at least 0.70. / In grassetto, i coefficienti di correlazione di almeno 0.70. **NOTE:** provinces with at least 50 participants who responded to the NINFEA questionnaire on COVID-19 were considered: Alessandria, Asti, Cuneo, Turin (Piedmont Region); Arezzo, Florence, Lucca (Tuscany Region); Milan (Lombardy Region), Rome (Lazio Region). / **NOTA:** sono state considerate le province con almeno 50 partecipanti che hanno risposto al questionario NINFEA sul COVID-19: Alessandria, Asti, Cuneo, Torino (Piemonte), Arezzo, Firenze, Lucca (Toscana), Milano (Lombardia), Roma (Lazio).

<sup>a</sup> Excluding anosmia/dysgeusia and breathing difficulties. / Escludendo anosmia/dysgeusia e difficoltà respiratorie. <sup>b</sup> Nasopharyngeal swabs for SARS-CoV-2 testing. / Tampone rinofaringeo per test di SARS-CoV-2.

**Table 3.** Geographical correlation between SARS-CoV-2 population cumulative incidence and COVID-19-like symptoms, testing and diagnosis in the NINFEA population.

**Tabella 3.** Correlazione geografica tra l'incidenza cumulativa di casi di COVID-19 per provincia e sintomi, test e diagnosi di COVID-19 nella popolazione NINFEA.

SARS-COV-2 TEST <sup>a</sup> / COVID-19 DIAGNOSIS	NASAL CONGESTION	FEVER 37.5-37.9°C	FEVER >37.5°C	SORE THROAT	COUGH	MUSCLE PAIN	FATIGUE	NAUSEA/ VOMITING	DIARRHOEA	ANOSMIA/ DYSGEUSIA <sup>b</sup>	BREATHING DIFFICULTIES <sup>b</sup>	AT LEAST ONE SYMPTOM <sup>c</sup>
<b>CHILDREN (N. 5,667)<sup>d</sup></b>												
1.00 (reference)												
No family member tested N. 5,372 (94.8%)												
At least one tested family member but none with COVID-19 N. 244 (4.3%)	0.86 (0.55-1.34)	1.28 (0.65-2.54)	1.26 (0.86-1.85)	0.83 (0.47-1.46)	0.94 (0.59-1.50)	1.02 (0.51-2.05)	1.01 (0.50-2.04)	1.23 (0.61-2.46)	1.25 (0.74-2.12)	– <sup>e</sup>	2.50 (0.71-8.76)	0.98 (0.76-1.27)
At least one family member with COVID-19 N. 51 (0.9%)	0.57 (0.14-2.27) <sup>f</sup>	4.54 (2.20-9.40)	1.11 (0.37-3.35)	0.62 (0.16-2.44) <sup>f</sup>	0.38 (0.09-1.53) <sup>f</sup>	0.56 (0.08-3.74) <sup>f</sup>	1.47 (0.49-4.37) <sup>f</sup>	– <sup>e</sup>	2.24 (0.85-5.94)	24.50 (3.47-172.9) <sup>f</sup>	– <sup>e</sup>	1.23 (0.73-2.06)
<b>ADULTS (N. 6,117)<sup>g</sup></b>												
1.00 (reference)												
No family member tested N. 5,795 (94.7%)												
At least one tested family member but none with COVID-19 N. 269 (4.4%)	0.87 (0.59-1.29)	1.26 (0.77-2.06)	2.18 (1.47-3.23)	1.21 (0.88-1.66)	1.53 (1.16-2.01)	1.17 (0.81-1.69)	1.33 (1.00-1.78)	1.58 (0.81-3.06)	1.54 (1.01-2.34)	1.62 (0.62-4.25)	1.51 (0.61-3.77)	1.15 (0.97-1.37)
At least one family member with COVID-19 N. 53 (0.9%)	1.45 (0.76-2.76)	4.28 (2.44-7.49)	8.68 (6.10-12.3)	1.93 (1.14-3.25)	3.58 (2.63-4.87)	4.37 (3.20-5.97)	3.52 (2.75-4.50)	6.22 (3.45-11.2)	4.52 (3.06-6.68)	13.64 (7.34-25.4)	14.4 (7.98-26.0)	1.81 (1.49-2.19)
<b>SENSITIVITY ANALYSIS</b>												
At least one family member with COVID-19 – COVID-19 cases excluded N. 23 (0.4%)	0.37 (0.06-2.50)	2.28 (0.64-8.14)	2.44 (0.62-9.68)	1.37 (0.48-3.91)	2.21 (1.02-4.81)	2.50 (1.16-5.36)	1.99 (1.02-3.89)	1.86 (0.26-13.11)	3.13 (1.31-7.53)	12.58 (4.70-33.68)	6.55 (1.75-24.55)	0.99 (0.54-1.80)

<sup>a</sup> Nasopharyngeal swabs for SARS-CoV-2 testing. / Tampone rinofaringeo per test di SARS-CoV-2. <sup>b</sup> Based of 3,605 children aged  $\geq 6$  years and 3,938 adults. / Basato su 3.605 bambini  $\geq 6$  anni e 3.938 adulti. <sup>c</sup> Excluding anosmia/dysgeusia and breathing difficulties. / Escludendo anosmia/dysgeusia e difficoltà respiratorie. <sup>d</sup> Adjusted for child gender, age, maternal age, and education level, family size, residential area, and region of residence. / Aggiustato per genere ed età del bambino, età materna, livello di istruzione della madre, dimensione della famiglia, area di residenza e regione di residenza. <sup>e</sup> No exposed cases. / Nessun caso esposto. <sup>f</sup> Based on less than 5 exposed cases. / Basato su meno di 5 casi esposti. <sup>g</sup> Adjusted for age, gender, maternal education level, family size, residential area, and region of residence. / Aggiustato per età, genere, livello d'istruzione della famiglia, area di residenza e regione di residenza.

**Table 4.** Adjusted prevalence ratios and 95% confidence intervals of selected symptoms for negative SARS-CoV-2 testing and COVID-19 diagnosis within the family.  
**Tabella 4.** Rapporti di prevalenza aggiustati e i rispettivi intervalli di confidenza al 95% per il test SARS-CoV-2 negativo e la diagnosi di COVID-19 all'interno della famiglia.

SYMPTOMS <sup>a</sup>	SENSITIVITY (95%CI) <sup>b</sup> AMONG NINFEA PARTICIPANTS	PPV (95%CI) <sup>b</sup> AMONG NINFEA PARTICIPANTS TESTED FOR SARS-COV-2 <sup>c</sup>	NPV (95%CI) <sup>b</sup> AMONG NINFEA PARTICIPANTS TESTED FOR SARS-COV-2 <sup>c</sup>	PPV (95%CI) <sup>b</sup> AMONG NINFEA PIEDMONT RESIDENTS TESTED FOR SARS-COV-2 <sup>c</sup>	PPV (95%CI) <sup>b</sup> AMONG NINFEA PIEDMONT RESIDENTS
NASAL CONGESTION	30.0% (13.6-46.4)	32.1% (14.8-49.4)	86.5% (80.9-92.2)	36.8% (15.2-58.5)	1.4% (0.4-2.4)
FEVER 37.0-37.5°C	36.7% (19.4-53.9)	40.7% (22.2-59.3)	88.0% (82.7-93.4)	47.1% (23.3-70.8)	3.1% (1.0-5.3)
FEVER >37.5°C	70.0% (53.6-86.4)	44.4% (29.9-59.0)	93.5% (89.2-97.9)	51.7% (33.5-69.9)	7.3% (3.9-10.8)
SORE THROAT	36.7% (19.4-53.9)	26.8% (13.3-40.4)	86.7% (80.8-92.6)	32.1% (14.8-49.4)	1.5% (0.5-2.5)
COUGH	60.0% (42.5-77.5)	32.1% (19.9-44.4)	91.2% (85.9-96.4)	36.8% (21.5-52.2)	2.6% (1.3-4.0)
MUSCLE PAIN	70.0% (53.6-86.4)	42.9% (29.0-56.7)	94.2% (90.0-98.4)	55.2% (37.1-73.3)	3.6% (1.9-5.4)
FATIGUE	80.0% (65.7-94.3)	36.5% (24.6-48.4)	95.3% (91.2-99.3)	43.9% (28.7-59.1)	2.9% (1.6-4.2)
NAUSEA/VOMITING	30.0% (13.6-46.4)	60.0% (35.2-84.8)	87.7% (82.5-92.9)	60.0% (29.6-90.4)	5.4% (1.2-9.6)
DIARRHOEA	40.0% (22.5-57.5)	35.5% (18.6-52.3)	87.7% (82.2-93.2)	40.0% (18.5-61.5)	3.1% (1.0-5.1)
ANOSMIA/DYSGEUSIA	42.9% (16.9-68.8)	50.0% (19.0-81.0)	91.6% (86.0-97.2)	83.3% (53.5-100.0)	7.7% (1.2-14.2)
BREATHING DIFFICULTIES	57.1% (31.2-83.1)	61.5% (35.1-88.0)	94.6% (89.9-99.2)	88.9% (68.4-100.0)	10.8% (3.7-17.9)
ESTIMATED A PRIORI COVID-19 PREVALENCE	–	16.6%	16.6%	18.5%	0.54%

<sup>a</sup> Based on 6,133 NINFEA participants (3,948 among Piedmont residents) for all symptoms but anosmia/dysgeusia and breathing difficulties which estimates are based on 3,938 NINFEA participants (2,552 from Piedmont). / Basato su 6.133 partecipanti NINFEA (3.948 tra i residenti in Piemonte) per tutti i sintomi tranne anosmia/disgeusia e difficoltà respiratorie le cui stime sono basate su 3.938 partecipanti NINFEA (2.552 residenti in Piemonte).

<sup>b</sup> Wald binomial confidence intervals. / Intervalli di confidenza binomiali di Wald.

<sup>c</sup> Nasopharyngeal swabs for SARS-CoV-2 testing. / Tampone rinofaringeo per test di SARS-CoV-2.

**Table 5.** Sensitivity, positive predictive values (PPVs), and negative predictive values (NPVs) of COVID-19 diagnosis for COVID-19-like symptoms in adults.

**Tabella 5.** Sensibilità, valori predittivi positivi (PPV) e negativi (NPV) della diagnosi di COVID-19 per sintomi tipici del COVID-19 negli adulti.

Increased prevalence ratios, although of a lower magnitude, were observed when comparing adults with at least one family member who tested negative for SARS-CoV-2 with adults from untested households. Conversely, in children having a family member who tested negative for SARS-CoV-2 was not associated with an increased prevalence of any of the symptoms.

#### SENSITIVITY, PPVS AND NPVS OF COVID-19-LIKE SYMPTOMS IN THE ADULT NINFEA POPULATION

Table 5 shows sensitivity, PPVs, and NPVs of COVID-19 diagnosis for COVID-19-like symptoms in adults tested for SARS-CoV-2. Sensitivities higher than 70% were observed for fatigue, fever >37°C, and muscle pain (Table 5). The analyses restricted to the tested NINFEA Piedmont residents revealed similar PPVs as for the full cohort, with higher PPVs for breathing difficulties (88.9%; 95%CI 68.4-100.0) and the loss of taste or smell (83.3%; 95%CI 53.5-100.0). In the entire NINFEA Piedmont population, with a COVID-19 prevalence of 0.54% (Table 5, last column), breathing difficulties, anosmia/dysgeusia, and fever >37°C had the highest PPVs (10.8%, 7.7%, and 7.3%, respectively).

## DISCUSSION

Data obtained from the members of an ongoing cohort of Italian children and their family members, mainly from Northern Italy, were used to study COVID-19-like symptoms in children and adults during the initial phases of the COVID-19 epidemic. In the 6-8 weeks since the first known autochthonous Italian COVID-19 case, more than a half of the interviewed families had at least one family member with at least one COVID-19-like symptom. Overall, adults reported a relatively high prevalence of fatigue, cough, sore throat, nasal congestion, and muscle pain, while in children the most frequent symptoms included nasal congestion, cough, and fever. While COVID-19-like symptoms were quite frequent, the prevalence of diagnosed COVID-19 in the cohort was 0.5% among adults, close to 0% among children, and 16.6% among adults tested for SARS-CoV-2. This may suggest that COVID-19-like symptoms are in general not highly specific and/or that SARS-CoV-2 infection is underdiagnosed, especially in children. These two aspects were further explored in this study at an ecological and individual level. Ecologically, there was a strong correlation between the prevalence of muscle pain, fatigue, low-grade fever, and breathing difficulties in adults and the population cumu-

lative number of SARS-CoV-2 cases. In children, a similar geographical correlation was found only for the prevalence of muscle pain and fatigue, which were likely driven by parental symptoms and possible differential reporting (i.e., parents with muscle pain more likely report muscle pain in their children). Consistent with other studies,<sup>6,10,18,19</sup> the findings here presented suggest that monitoring the prevalence of COVID-19-like symptoms in adults, but not in children, may serve as an alert of changes in disease activity and may inform about local disease clusters.

It has been reported that most COVID-19 cases had either documented contact with an infected case or were part of family clusters.<sup>4,20-23</sup> In a report based on 171 COVID-19-positive children, 90.1% of cases came from COVID-19 positive families.<sup>4</sup> In this paper, the prevalence of COVID-19-like symptoms in the presence of a family member with COVID-19 was examined. In children, exposure to COVID-19 within the family was associated with a strongly increased prevalence of low-grade fever (37.0-37.5°C) and anosmia/dysgeusia, but with no other symptoms. This is consistent with previous findings that children are often asymptomatic,<sup>4,24,25</sup> but, when they are symptomatic, fever is the most frequent symptom, with a reported prevalence between 40% and 56%.<sup>4,25-28</sup> It is possible that children from COVID-19 positive families have a mild presentation of the disease without receiving diagnosis and escaping the surveillance systems. Additionally, this finding was confined to low-grade fever, suggesting that in children low-grade fever may be more specific to SARS-CoV-2 infection than fever above 37.5°C.

On the other hand, the analyses in adults showed a clear pattern of familiar symptom aggregation. Adults in households with at least one family member diagnosed with COVID-19 had a higher prevalence of almost all symptoms compared with adults with no family member tested for SARS-CoV-2. The same symptoms were also associated with SARS-CoV-2 negative testing in the household, suggesting that testing was also performed for symptoms caused by infectious diseases other than COVID-19. The most relevant symptoms in adults exposed to COVID-19 within the family included breathing difficulties, anosmia/dysgeusia, muscle pain, fatigue, cough, and diarrhoea. This is consistent with other studies reporting the patterns of symptoms in adults with COVID-19.<sup>6,25,29,30</sup> Consistent with the results here presented, loss of smell or taste has been reported to be one of the strongest predictors of COVID-19.<sup>6,30</sup> The presence of these symptoms among adult family members of COVID-19 cases is suggestive of COVID-19 transmission within a family; testing of symptomatic adults and, possibly, children with low fever is a key to prevent further community transmission.

Although the presence of symptoms is one of the main indications for testing, especially when contact tracing is unable to cope with an increasing number of diagnosed cases, among tested individuals in the NINFEA population, only

anosmia/dysgeusia and breathing difficulties reached a PPV above 80% (in Piedmont residents, lower in the full population), and no symptom had a PPV of at least 90%; similarly, only breathing difficulties, fatigue, and muscle pain had an NPV close to 95%. Finally, PPVs for SARS-CoV-2 positive testing in the population varied between 1% and 11%, with an a-priori probability of 0.5%. These PPVs are the consequence of both the local testing approach and the PPV among tested individuals. COVID-19 testing practices in Italy differ across regional jurisdictions; they changed during the phases of the outbreak and differ across age groups. The present estimates of sensitivity and predictive values, thus, depend on these contextual variables, which may detract from their generalizability to other contexts.

The population surveyed was composed of children and their family members who are participating in a web-based birth cohort established in 2005 and followed-up for many years now. Therefore, the estimates are based on the well-known underlying population, and are less prone to selection bias due to outcome-driven participation. In this study, the response proportion to the COVID-19 survey was approximately 55%, but respondents were similar to non-respondents regarding baseline characteristics, and there was no evidence of an association between late response and the prevalence of symptoms.

Although no information on the temporal relationship between the onset of symptoms and diagnosis was available, the study period is a maximum of 6-8 weeks and it is relatively unlikely that in such a short period, the symptoms could be due to other conditions. This is, indeed, one of the main strengths of this study, which was able to focus on a relatively short time period during which the first wave of COVID-19 epidemic peaked in Italy, while the ability of the surveillance system to detect the cases was rather low due to lack of preparedness. All information collected in the study was reported by one member of the family on behalf of all members, possibly leading to misclassification. This is especially true for less severe symptoms (e.g., nasal congestion) with short duration, while no misclassification is expected for hard variables such as SARS-CoV-2 swab testing and COVID-19 diagnosis.

## CONCLUSIONS

This study found that the prevalence of certain symptoms may be relevant for the identification of future local disease clusters and that symptoms in family members of confirmed COVID-19 cases could help identify the intrafamilial spread of the virus and its further propagation in the community. Despite the high population prevalence and low specificity of most of the COVID-19-like symptoms, some of these symptoms may inform future tracing of infected individuals, especially in cases when mass or even only symptomatic individuals' swab testing is impossible.

**Conflicts of interest:** none declared.

**Acknowledgements:** the Authors are grateful to Paola Ivaldi, Sonia Barcellari, Fabio Saccona, Francesco Brunetti, Ugo Casalone, and to all the participants of the NINFEA cohort for their continuous contribution to the NINFEA cohort.

**Funding:** the NINFEA study was partially funded by the Compagnia San Paolo Foundation, which had no role in the design of the study, collection, analysis, or interpretation of data.

## REFERENCES

- Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis* 2020;94:154-55.
- Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395(10223):514-23.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID 19) outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323(13):1239-42.
- Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. *N Engl J Med* 2020; 382(17):1663-65.
- Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory Coronavirus 2 infection: a cross-sectional study. *Clin Infect Dis* 2020;71(15):889-90.
- Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med* 2020;26(7):1037-40.
- World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance, 21 March 2020. Geneva, WHO, 2020. Available from: <https://apps.who.int/iris/handle/10665/331509> (last accessed: 09.11.2020).
- Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 27 ottobre 2020 – ore 11:00. Roma, ISS, 2020. Available from: [https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_27-ottobre-2020.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_27-ottobre-2020.pdf) (last accessed: 05.11.2020).
- Istituto Superiore di Sanità. Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2. Roma, ISS, 2020. Available from: <https://www.istat.it/it/files/2020/08/ReportPrimiRisultatiIndagineSiero.pdf> (last accessed: 09.11.2020).
- Drew DA, Nguyen LH, Steves CJ, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. *Science* 2020;368(6497):1362-67.
- Richiardi L, Baussano I, Vizzini L, et al. Feasibility of recruiting a birth cohort through the Internet: the experience of the NINFEA cohort. *Eur J Epidemiol* 2007;22(12):831-37.
- Firestone R, Cheng S, Pearce N, et al. Internet-based birth-cohort studies: is this the future for epidemiology? *JMIR Res Protoc* 2015;4(2):e71.
- Blumenberg C, Zugna D, Popovic M, Pizzi C, Barros AJD, Richiardi L. Questionnaire breakoff and item nonresponse in web-based questionnaires: multilevel analysis of person-level and item design factors in a birth cohort. *J Med Internet Res* 2018;20(12):e11046.
- Bajardi P, Paolotti D, Vespignani A, et al. Association between recruitment methods and attrition in Internet-based studies. *PLoS One* 2014;9(12):e114925.
- Presidenza del Consiglio dei Ministri, Dipartimento della Protezione Civile. COVID-19 Italia. Monitoraggio situazione. 2020. Available from: <https://github.com/pcm-dpc/COVID-19> (last accessed: 22.04.2020).
- Italian National Institute of Statistics (ISTAT). Popolazione residente al 1° gennaio. Available from: <http://dati.istat.it/> (last accessed: 22.04.2020).
- Battaglia MP, Frankel MR, Link MW. Improving standard poststratification techniques for random-digit-dialing telephone surveys. *Survey Res Methods* 2008;2(1):11-19.
- Bowyer RCE, Varsavsky T, Sudre CH, et al. Geo-social gradients in predicted COVID-19 prevalence and severity in Great Britain: results from 2,266,235 users of the COVID-19 Symptoms Tracker app. *medRxiv* 27.04.2020. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.23.20076521v1> (last accessed: 27.10.2020).
- Williams FMK, Freydn MB, Mangino M, et al. Self-reported symptoms of COVID-19 including symptoms most predictive of SARS-CoV-2 infection, are heritable. *Twin Res Hum Genet* 2020;23(6):316-21.
- Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020;80(4):401-06.
- Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. *Pediatrics* 2020;145(6):e20200702.
- Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households – Tennessee and Wisconsin, April–September 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(44):1631-34.
- Madewell ZJ, Yang Y, Longini Jr. JM, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3(12):e2031756.
- Tagarro A, Epalza C, Santos M, et al. Screening and severity of Coronavirus Disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr* 2020:e201346.
- CDC COVID-19 Response Team. Coronavirus disease 2019 in children – United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(14):422-26.
- Chen A, Huang J, Liao Y, et al. Differences in clinical and imaging presentation of pediatric patients with COVID-19 in comparison with adults. *Radiol Cardiothorac Imaging* 2020;2(2):e200117.
- Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 2020;20(6):689-96.
- de Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB. Clinical manifestations of children with COVID-19: A systematic review. *Pediatr Pulmonol* 2020;55(8):1892-99.
- Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect* 2020;80(6):656-65.
- Zens M, Brammertz A, Herpich J, Südkamp N, Hinterseer M. App-based tracking of self-reported COVID-19 symptoms: analysis of questionnaire data. *J Med Internet Res* 2020;22(9):e21956.